No-one even knows if it is possible to make a vaccine against COVID-19 and already there is an escalating row about cost and equitable access if one succeeds in clinical trials.
Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical t
In a landmark study, thousands of NHS patients will have their DNA studied to see how a person’s genetic profile plays a role in susceptibility to COVID-19.
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark
Genfit has seen almost two-thirds of the value wiped off its shares after its much-anticipated pivotal trial of non-alcoholic steatohepatitis (NASH) drug elafibranor turned out